Updated: Sep 2
What Howard Rudzki Says:
Encouraging! If this works, it could add 500 million to 1 million doses per year.
Moderna Inc, an American biotech company focused on drug discovery, said that the U.S. government’s Biomedical Advanced Research and Development Authority (BARDA) has committed an additional $472 million in funding to support scaling up of manufacturing and clinical development of its novel coronavirus vaccine.
That additional commitment would support late-stage clinical development including the expanded Phase 3 study of the Company’s mRNA vaccine candidate (mRNA-1273) against COVID-19.
The total value of the award is now approximately $955 million from the BARDA, including $483 million which the U.S.-based drugmaker received in April.
Moderna said it remains on track to be able to deliver approximately 500 million doses per year and possibly up to 1 billion doses per year, beginning in 2021 from the company’s internal U.S. manufacturing site and strategic collaboration with Lonza.